Welcome to our dedicated page for Organigram Global news (Ticker: OGI), a resource for investors and traders seeking the latest updates and insights on Organigram Global stock.
Organigram Holdings Inc (OGI) is a leading Canadian licensed cannabis producer specializing in premium medical and recreational products through advanced indoor cultivation. This news hub provides investors and industry observers with essential updates on OGI's operational developments, regulatory compliance, and market positioning.
Track official press releases covering quarterly earnings, product innovations, strategic partnerships. Access timely updates on regulatory milestones and cultivation advancements within Canada's dynamic cannabis sector. Our curated collection ensures transparent monitoring of OGI's financial performance and brand portfolio growth.
Key updates include medical cannabis research initiatives, recreational market expansions, and sustainability efforts. Bookmark this page for centralized access to OGI's corporate communications, enabling informed analysis of their market leadership in organic cannabis production.
Flow Beverage Corp. (OTCQX: FLWBF; TSX: FLOW) has appointed Stephen A. Smith and Michael Lines to its Board of Directors. Smith, with a strong background in finance, will chair the Audit Committee, while Lines, founder of Wellness Natural Inc., will chair the Governance, Human Resources & Compensation Committee. Their appointments aim to enhance Flow's strategic transformation and focus on profitable growth in the consumer packaged goods sector. Flow is recognized as one of North America's fastest-growing premium water companies, emphasizing sustainable practices and health-oriented products.
Organigram Holdings reported a record net revenue of $45.5 million for Q4 Fiscal 2022, an 83% increase year-over-year, and $145.8 million for the fiscal year, up 84%. Adjusted EBITDA stood at $3.2 million for Q4, marking the third consecutive quarter of positive EBITDA, compared to a loss of $4.8 million in the prior year. The company achieved significant market share gains, holding the #1 position in Ontario and the Maritimes. With expanded capacity and operational efficiencies, Organigram is poised for continued growth in Fiscal 2023.
Organigram Holdings Inc. (NASDAQ: OGI) has announced the launch of its new value brand, HOLY MOUNTAIN, focused on affordable whole flower and concentrates. The initial offerings include dried flower strains like R*NTZ and MAC-1, alongside a pressed hash product. This expansion aims to enhance accessibility for consumers across Canada. Organigram is a leading cannabis producer, with plans to continue innovating and responding to consumer demands.
Organigram Holdings Inc. (NASDAQ: OGI) will report its earnings results for the fiscal year and fourth quarter ended August 31, 2022 on November 28, 2022, after market close. The company will conduct a conference call on November 29, 2022, at 8:00 am ET, to discuss these results. Interested participants can register for the call through a provided link. Organigram is a leading cannabis producer in Canada, focused on high-quality cannabis products for patients and recreational consumers.
Organigram is set to supply InterCure with up to 20,000 kg of dried cannabis flower over several years, following a successful 3,000 kg supply agreement fulfilled since June 2020. This new multi-year agreement includes an initial commitment of 10,000 kg with an option for an additional 10,000 kg within three years. Approximately 2,800 kg has already been delivered. The collaboration aims to support both companies’ international expansion strategies, contingent upon compliance with local regulations.
Organigram achieved a record net revenue of $38.1 million in Q3 Fiscal 2022, marking an 88% increase from the previous year. Gross revenue also saw a 90% rise to $55.2 million. The company maintained a 7.8% market share among Canadian licensed producers and remained the top player in dried flower products. New SKUs were introduced, including SHRED-X vapes and CBN Bedtime Blueberry Lemon gummies. However, net loss decreased to $2.8 million, and cash reserves fell by 31% year-over-year.
Organigram Holdings Inc. (NASDAQ: OGI) announced it will report its earnings results for Q3 2022, ending May 31, 2022, on July 14, 2022, before the market opens. A conference call is scheduled for the same day at 8:00 am Eastern Time to discuss the results. Interested participants can register through provided links and access the live call or a replay later. Organigram, a licensed producer of cannabis and cannabis-derived products in Canada, focuses on high-quality products for patients and adult recreational consumers.
Organigram Holdings (OGI) announced its Q2 results ending February 28, 2022, showcasing a remarkable 128% increase in gross revenue to $43.9 million and a net revenue surge of 117% to $31.8 million, marking the highest in company history. The company achieved positive Adjusted EBITDA of $1.6 million two quarters earlier than forecasted. Additionally, it gained a 8.2% market share in Canada, maintaining its top position in the dried flower category. The successful integration of the Laurentian acquisition further boosts its portfolio and market presence.
Organigram Holdings Inc. (NASDAQ: OGI), a top cannabis producer, will report its second quarter 2022 earnings results on April 12, 2022, prior to market opening. The Company will hold a conference call on the same day at 8:00 am ET to discuss the results. Interested parties can register for the call through a provided link and also access a webcast of the discussion. A replay will be available within 24 hours after the call concludes. Organigram focuses on producing quality cannabis products and expanding its international presence.
Organigram Holdings Inc. (NASDAQ: OGI) reports strong market share growth, maintaining the #3 position among Canadian licensed producers and the #1 position in dried flower. The integration of Laurentian Holdings is on track, with expected expansion of its distribution network across nine provinces. New product launches include premium dried flower strains and SHRED’ems line extensions, indicating a commitment to innovation and consumer demand. Overall, these developments support Organigram's market strategy and potential for continued growth.